Skip to main content

Maximizing the Goals of the Cures Acceleration Network (CAN) to Accelerate the Development of New Drugs and Diagnostics: A Workshop

Completed

This public workshop provided a venue for stakeholders to discuss the options and opportunities to maximize the usefulness and impact of the National Center for Advancing Translational Sciences (NCATS) Cures Action Network. Furthermore, this workshop informed NCATS in its efforts to implement CAN and advance translational sciences. The workshop was hosted by the National Academies Forum on Drug Discovery, Development and Translation.

The workshop was held on June 4, 2012. Please visit our event page for additional information and meeting materials for the workshop.

Description

An ad hoc planning committee will plan a two-day public workshop that will explore ways to maximize the usefulness and impact of the Cures Acceleration Network (CAN) in order to advance translational sciences, a key goal of NCATS. Specifically, the workshop will include consideration of the effective use of CAN authorities for the development of new tools and methods to enhance the development and testing of therapies and diagnostics to patients. Subject matter experts will be invited to participate in the workshop to discuss and help explore models, approaches, and strategies to accelerate translational science. The workshop will feature invited presentations and discussions that will:

  • Identify and catalog potential tools, methods, and approaches that hold promise for accelerating translational science. Consideration of such promising approaches will draw from the experiences of existing activities at other federal agencies related to the goals of CAN (e.g., FDA, CDC, AHRQ).
  • Discuss the authorities conferred to CAN and identify strategies for effectively using those authorities. Consideration of the CAN authorities will specifically explore the flexible research, or “other transactions”, authority and will reference existing efforts in which such authority is currently applied across other federal agencies (e.g., DARPA, DTRA, BARDA).
  • Explore promising models for public-private collaborations that could be strengthened or facilitated by activities under CAN. Discuss barriers to such collaborations and identify opportunities and potential solutions for moving past the identified barriers. Discuss the respective roles of multiple sectors, including, e.g., biopharma, biotech, venture capital/private equity, and patient/disease advocacy.
  • Identify barriers and potential solutions to facilitate coordination of activities under CAN with the FDA regulatory review process and timelines.

The planning committee will develop the agenda for the workshop, select and invite speakers and discussants, and moderate or identify moderators for the discussions. A single individually authored summary of the workshop will be prepared by a designated rapporteur based on the information gathered and the discussions held during the workshop.

Collaborators

Sponsors

Department of Health and Human Services

Private: For Profit

Private: Non Profit

Staff

Anne Claiborne

Lead

Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.